[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Report Package: Hot targets for empowered antibody and cell therapy technologies

December 2016 | 202 pages | ID: R7CCE445BF2EN
La Merie Publishing

US$ 2,090.00

Online Subscription

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Report Package: Hot targets for empowered antibody and cell therapy technologies

This package contains three reports analyzing
  • BCMA,
  • CD123 and
  • CD22
as versatile and hot targets for the successful application of empowered antibody and cell technologies, including:
  • Fc-Engineered Antibodies;
  • Radioimmunotherapy;
  • Immunotoxins;
  • Antibody-Drug Conjugates;
  • T-Cell Redirecting Bispecific Antibodies;
  • Chimeric Antigen Receptor (CAR) T-Cells.
The reports describe and discuss
  • Target background, scientific rationale & expression profiles;
  • Preclinical proof-of-concept;
  • Clinical experience;
  • Competitive landscape;
  • Drug or cell therapy profiles;
  • Company profiles.
Each of the three reports can be obtained individually, but the package of the three reports provides a 40% discount on the regular prices:Detailed report descriptions, tables of contents and samples from the reports can be found on the respective product page.
REPORT 1:

B-CELL MATURATION ANTIGEN (BCMA): HOT TARGET FOR EMERGING TREATMENT MODALITIES

Target Background
Target Antigen Expression Profile
Preclinical Proof-of-Concept
Clinical Indications & Treatment Options
Clinical Experience with BCMA-Targeted Treatment Modalities
Treatment Modalities & Competitive Landscape
  Drug & Cell Therapy Candidate Profiles
  CAR T-Cells
  Antibody-Drug Conjugate (ADC)
  T-Cell Redirecting Antibodies
Company Profiles
References

REPORT 2:

CD123: A PARADIGMATIC TARGET FOR IMMUNOTHERAPEUTIC TREATMENT MODALITIES

Target Background & Scientific Rationale
Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics
Clinical Experience with CD123-Targeted Treatment Modalities
Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD123 Immunotherapeutics:
  Immunotoxins
  Naked Antibody
  Fc-Engineered Antibodies
  Antibody-Drug Conjugates
  T-Cell Redirecting Bispecific Antibodies
  Anti-CD123 CAR T-Cells
Company Profiles
References
ADDENDUM: Competitor Analysis of CD123-Targeted Immunotherapeutics

REPORT 3:

CD22: A SUITABLE ANTIGEN FOR TARGETED PAYLOAD DELIVERY BY IMMUNOTHERAPEUTICS

Target Background & Scientific Rationale
Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD22 Immunotherapeutics
  Naked antibodies;
  Radioimmunotherapy (RIT);
  Immunotoxins (IT);
  Antibody-Dug Conjugates (ADC); and
  Chimeric Antigen Receptor (CAR) T-Cells.
Profiles of Companies with CD22-Targeted Immunotherapeutics
References
ADDENDUM: Competitor Analysis of of CD22-Targeted Immunotherapeutics


More Publications